Platinum-Sensitive Lung Small Cell Carcinoma
4 clinical trials · Condition
◉ Watch Platinum-Sensitive Lung Small Cell Carcinoma
| Record | Firm | Date |
|---|---|---|
| Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer (NCT05572476) | Institut Bergonié | 2023-10-01 |
| Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer (NCT05353439) | National Cancer Institute (NCI) | 2022-07-27 |
| Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer (NCT04607954) | Mayo Clinic | 2020-12-04 |
| Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs (NCT03896503) | National Cancer Institute (NCI) | 2019-12-30 |
Track Platinum-Sensitive Lung Small Cell Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.